This site provides INTERCEPT product information for Health Care Professionals in the United States.

Cerus Websites

INTERCEPT Pathogen-Reduced Plasma

Reduce Patient Risk of Transfusion Transmitted Infection

What is INTERCEPT Plasma?

The INTERCEPT Blood System for Plasma, pathogen reduction system, provides broad-spectrum reduction of pathogens and leukocytes, reducing the risks of transfusion-transmitted infection (TTI) from known and emerging pathogens, as well as transfusion-associated graft-versus-host disease (TA GvHD). INTERCEPT-treated plasma has a proven track record of safety and has demonstrated equivalent therapeutic efficacy to conventional plasma in clinical trials. Furthermore, the INTERCEPT treatment for plasma and platelets can occur on the same Illuminator platform for optimal efficiency.

Broad spectrum of pathogens inactivated by the INTERCEPT Blood System for Plasma1

GRAM-NEGATIVE BACTERIA

Klebsiella pneumoniae
Yersinia enterocolitica
Pseudomonas aeruginosa
Enterobacter cloacae
Anaplasma phagocytophilum

GRAM-POSTIVE BACTERIA

Staphylococcus epidermidis
Staphylococcus aureus

ENVELOPED and
NON-ENVELOPED VIRUSES

HIV-1
DHBV (model for HBV) 
BVDV (Model for HCV) 
HTLV-I
HTLV-II
WNV
Chikungunya
Influenza A
SARS-Associated Coronavirus
Parvovirus B-19
Bluetongue Virus
Adenovirus

 

PROTOZOA

Trypanosoma cruzi 
Plasmodium falciparum
Babesia microti 

SPIROCHETES

Treponema pallidum 
Borrelia burgdorferi 

LEUKOCYTES

Human T-Cells 

There is no pathogen inactivation process that has been shown to eliminate all pathogens. Certain non-enveloped viruses (e.g., HAV, HEV, B19 and poliovirus) and Bacillus cereus spores have demonstrated resistance to the INTERCEPT process. For a full list of pathogens, please refer to package inserts.

1. INTERCEPT Blood System for Plasma [Package Insert]. Concord, CA: Cerus Corporation; May 1, 2020.